CD4 and non-small cell lung carcinoma: There are also data from a posthoc analysis of a clinical trial in patients with NSCLC treated with neoadjuvant immunotherapy, which found a relationship between higher baseline CD4+ PD-1+ T-cell levels and a higher response to treatment [49].